A Solid Vaccine Stock Ready to Pop

Biotech and pharmaceutical stocks have been in the spotlight a great deal over the last few quarters. The race to find a vaccine has produced a number of winners and losers as results for trials were announced.

The most recent winner appears to be Pfizer (PFE). The company announced trial results showing that 90% of those given the vaccine were protected from the COVID-19 virus.

One biotech company that is working with a couple of other companies on a vaccine and treatments is Amgen (AMGN). The company has partnered with Eli Lilly on their antibody therapy and it is working with Adaptive on both treatment and preventive drugs for the virus.

Despite its participation in the COVID-19 treatment and vaccine efforts, Amgen saw its stock slide in the four months.

It fell from the $260 area in early July to a low of $210.28 in the final week of October. The stock has since reversed and appears ready to resume its long-term upward trend.

Looking at the weekly chart we see a trend channel that has formed over the last few years. The lows from mid-2019 connect to form the lower rail and while the stock’s recent decline took it below that trend line, it closed the week right on it.

The only other time the stock fell below that trend line was during the market meltdown in March. We also see how the highs from last December and this past July connect with a parallel line.

Another factor that got my attention on Amgen’s chart was how the weekly stochastic indicators made a bullish crossover in the last few weeks.

In the past, when the stock has become oversold and the indicators have made a bullish crossover, we have seen extended rallies from Amgen. The rallies have produced gains between 23% and 27%. The low in March didn’t cause the indicators to reach oversold territory, but the stock rallied over 35% in two short months.

Management efficiency

While I like what is going on with the chart of Amgen, the reason it was on my radar in the first place was due to the fundamentals. The company has been able to grow earnings and revenue at a solid pace in recent years, but where the company does extremely well is with its management efficiency measurements.

The return on equity is 81.4% and that is extremely high. The average ROE tends to fall in the 15%-20% range. The profit margin is 45.5% and the average profit margin seems to be around 15%.

Despite the strong fundamentals, analysts are far less bullish on Amgen than they are the average stock. There are 29 analysts covering the stock with 13 “buy” ratings, 15 “hold” ratings, and one “sell” rating. This puts the buy percentage at 44.8% and the average buy percentage falls between 65% and 75%.

Why is it important that analysts are skeptical of the stock? When a stock has more hold and sell ratings than buy ratings, it means there is a greater chance for an upgrade or a series of upgrades that can help propel the stock higher.

Based on the previous rallies when the stochastic indicators made bullish crossovers, I look for Amgen to move up to the $265-$270 range in the next few months. With that in mind, I like the January 2021 $235-strike calls.

With the stock trading at $243.50, these options are priced at $15.95, or $1,595 for each contract. A move up to $265 would give the options an intrinsic value of $30.00 and that would mean a gain of 88% for investors.

Recommended Articles

Options: Why Buy Puts? To Make Money When You Think a Stock Will Fall in Price

Beginning options investors often struggle with the concept of put options. They have no trouble with call options. With calls, beginners usually grasp that you will buy a predetermined number

Bitcoin Zooming Higher Again. Speculation or the Future of Money?

As Bitcoin threatens to break through its record highs set a few years ago, at least some people are likely to get involved in speculating in them again. Many seem

5 Proven Ways to Earn Powerful Side Income

If you want to earn extra money with relative ease, whether it is to save up for retirement or prepare for a well-deserved vacation, one of the best things you

zto

Day Trading Now: Stock Too Expensive? Buy a Slice

The cost to build a diversified stock portfolio is often the highest barrier for new investors. The outlay required to buy a basket stocks is more than the dollars available.

Looking for Better Returns? 5 Ways to Invest in Brazil

Brazil is known for tourist attractions, its natural beauty and soccer. The former Portuguese colony is also a thriving multicultural country — a melting pot not unlike the United States.

Add Some Spice to Your Portfolio with This Consumer Staple Stock

When the vaccine results from Pfizer (PFE) were announced on November 9, it sent the stock market on a wild ride. Sectors that had been underperforming the overall market screamed

Iaccino: Market Volatility Here to Stay

Bob Iaccino, editor of the Stock Think Tank, talks about Amazon's move into prescription drugs and market volatility on Bloomberg News.

Beat the system by understanding both sides of the trade, reward and risk. Get Bob Iaccino's Stock Think Tank newsletter through this special offer.

Are Cannabis Stocks a Good Investment for 2021?

Cannabis and CBD oils are booming industries.  Economies see a massive boost of billions of dollars when these two hit the scene. From recreational to medicinal, these plants offer a

The Benefits and Pitfalls of Trading Options on ETFs

An exchange-traded fund (ETF) is a collection of assets that track specific investment categories. For instance, SPY tracks the S&P 500. ETFs can also track sectors and industries, such as

Options Strategy: Sell Covered Calls on Technology Stocks

Stock prices of publicly traded technology companies have been resilient this year. Many remained unaffected or benefited from the onset of the current crisis. Other sectors seem more exposed to

Looking for Foreign Stocks with Powerful Dividends? Look No More! (VYMI)

Declining yields on investment income products has let investors to hunt for high dividend yielding stocks to boost their income. One product that I have actively used and would like

Frazier: How I Got a 45.2% Gain in Less Than 60 Days

Click Here To Subscribe On A 100% Free-Trial Basis To The Bulletproof Wealth Report!

Hello David Frazier here, editor of the Bulletproof Wealth Report. I told subscribers to our Bulletproof Wealth Report on November 2nd that I expected U.S. stock prices